Tyrosine Kinase Inhibitors (TKI), Mitogen-activated Extracellular signal-regulated Kinase (MEK) and B- Rapidly Accelerated Fibrosarcoma (BRAF) kinase inhibitors and immunotherapy are currently used for treating thyroid cancer patients. Here, BRAF is linked to thyroid gland carcinoma.